ScholarIQanswers from OpenAlex & ORCID
Paul Emery
ResearcherPublications, citations & collaboration network
Paul Emery is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Paul Emery have?
ScholarIQindexed works
Paul Emery has 1,619 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Paul Emery have?
ScholarIQcitation count
Paul Emery has 130,110 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Paul Emery?
ScholarIQh-index
Paul Emery has an h-index of 159 in OpenAlex.
What is the i10-index of Paul Emery?
ScholarIQi10-index
Paul Emery has an i10-index of 790 in OpenAlex.
What is the ORCID of Paul Emery?
ScholarIQorcid
The ORCID for Paul Emery is on the source record.
What is the OpenAlex record for Paul Emery?
ScholarIQopenalex
The OpenAlex for Paul Emery is on the source record.
What are the most-cited papers on Paul Emery?
ScholarIQmost cited works
2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
Daniel Aletaha, Tuhina Neogi, Alan J. Silman, Julia Funovits, David T. Felson, Clifton O. Bingham, Neal S. Birnbaum, Gerd R Burmester, Vivian P. Bykerk, Marc D. Cohen, Bernard Combe, Karen H. Costenbader, Maxime Dougados, Paul Emery, Gianfranco Ferraccioli, Johanna M. W. Hazes, Kathryn Hobbs, T. Huizinga, Arthur Kavanaugh, Jonathan Kay, Tore K. Kvien, Timothy Laing, Philip J. Mease, Henri A. Ménard, Larry W. Moreland, Raymond L. Naden, Theodore Pincus, Josef S Smolen, Ewa Stanisławska‐Biernat, Deborah Symmons, Paul P. Tak, Katherine S. Upchurch, Jiří Vencovský, Frederick Wolfe, Gillian Hawker
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Peter E. Lipsky, Désirée van der Heijde, E. William St. Clair, Daniel E. Fürst, Ferdinand C. Breedveld, Joachim R. Kalden, Josef S Smolen, Michael H. Weisman, Paul Emery, Marc Feldmann, Gregory R. Harriman, Ravinder N. Maini
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
Josef S Smolen, Robert Landewé, J. W. J. Bijlsma, Gerd R Burmester, Maxime Dougados, Andreas Kerschbaumer, Iain B. McInnes, Alexandre Sepriano, Ronald van Vollenhoven, Maarten de Wit, Daniel Aletaha, Martin Aringer, Johan Askling, Alejandro Balsa, Maarten Boers, Alfons A den Broeder, Maya H Buch, Frank Buttgereit, Roberto Caporali, Myrna Cardiel, Diederik De Cock, Cătălin Codreanu, Maurizio Cutolo, Christopher J Edwards, Yvonne van Eijk‐Hustings, Paul Emery, Axel Finckh, Laure Gossec, Jacques‐Eric Gottenberg, Merete Lund Hetland, T. Huizinga, Marios Koloumas, Zhanguo Li, Xavier Mariette, Ulf Müller‐Ladner, Eduardo Mysler, José António Pereira da Silva, Gyula Poór, Janet Pope, Andrea Rubbert‐Roth, Adeline Ruyssen‐Witrand, Kenneth G. Saag, Anja Strangfeld, Tsutomu Takeuchi, Marieke Voshaar, René Westhovens, Désirée van der Heijde
Rheumatoid arthritis
Josef S Smolen, Daniel Aletaha, Anne Barton, Gerd R Burmester, Paul Emery, Gary S. Firestein, Arthur Kavanaugh, Iain B. McInnes, Daniel H. Solomon, Vibeke Strand, Kazuhiko Yamamoto
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
Ravinder N. Maini, E. William St. Clair, Ferdinand C. Breedveld, Daniel E. Fürst, Joachim R. Kalden, Michael H. Weisman, Josef S. Smolen, Paul Emery, Gregory R. Harriman, Marc Feldmann, Peter E. Lipsky